Ignite Creation Date:
2024-05-06 @ 8:05 PM
Last Modification Date:
2024-10-26 @ 3:20 PM
Study NCT ID:
NCT06244212
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-05-23
First Post:
2024-01-29
Brief Title:
Topical Treatment for Atopic Dermatitis
Sponsor:
Wake Forest University Health Sciences
Organization:
Wake Forest University Health Sciences
Study Overview
Official Title:
Topical Treatment for Atopic Dermatitis
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Medication adherence is a poorly studied phenomenon that challenges both patients and physicians 50 of individuals with chronic disease are not adherent to their medication regimen Within the United States non-adherence to medical treatment leads to approximately 100 billion in hospital admission costs While the issue of adherence is not limited to any particular field of medicine non-adherence occurs in approximately one-third to one-half of dermatological patients Non-adherence is of importance as it is a significant cause of treatment failure resulting in worse quality of life worse health outcomes and increased insurance costs
Detailed Description:
Unlike most modes of medication administration topical medications do not have a standardized method of dosage administration Although qualitative administration measures exist these measures are often arbitrary and not quantifiable ie a fingertip In such cases inappropriate dosing ie using too much or too little is an essential cause of treatment failure and measurements of adherence for topical medications should consider the amount of medication administered In a study analyzing the response to treatment in psoriatic patients patients who received a standardized dose of topical calcipotriol achieved a more significant decrease in mean Psoriasis Area and Severity Index PASI 47 compared to patients who were not standardized 17 P00001 Moreover over two-thirds of psoriatic patients deemed initially poor responders in the standardized regimen group were considered responsive to treatment after further consideration
Given topical options low cost efficacy and excellent safety profiles they are the first line treatment option for mild-to-moderate Atopic Dermatitis AD treatment This study will aim to assess differences in the amount of medication dispensed in two groups of patients with atopic dermatitis The first will undergo a brief educational demonstration by a trained professional to highlight the appropriate amount of topical medication to dispense for their disease involvement The second group will be a control group and receive the same medication however the Participants will receive standard of care education verbal and written instructions only Data from the two groups will be collected and analyzed to measure trends in dosing ie if the correct dosage quantity and frequency was dispensed
Given topical options low cost efficacy and excellent safety profiles they are the first line treatment option for mild-to-moderate Atopic Dermatitis AD treatment This study will aim to assess differences in the amount of medication dispensed in two groups of patients with atopic dermatitis The first will undergo a brief educational demonstration by a trained professional to highlight the appropriate amount of topical medication to dispense for their disease involvement The second group will be a control group and receive the same medication however the Participants will receive standard of care education verbal and written instructions only Data from the two groups will be collected and analyzed to measure trends in dosing ie if the correct dosage quantity and frequency was dispensed
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None